收稿日期: 2024-10-18
网络出版日期: 2025-01-26
基金资助
贵州省卫生健康委科学技术基金项目(gzwjkj2020-1-147)
Correlation between plasma ADAMTS13 level， disease severity and prognosis in patients with endometriosis
Received date: 2024-10-18
Online published: 2025-01-26
目的 探究子宫内膜异位症（EMS）患者血浆血管性血友病因子裂解蛋白酶（ADAMTS13）水平与病情严重程度的关系及其对预后的预测价值。 方法 回顾性选取2019年1月至2022年12月医院诊治的EMS患者130例。采用酶联免疫吸附法（ELISA）检测其血浆ADAMTS13水平，并分析其与美国生育协会（r-AFS）分期、子宫内膜异位症健康状况量表（EHP-30）评分的相关性。记录1年预后情况，logistic回归分析预后不良的危险因素。绘制受试者工作特征曲线（ROC）评估血浆ADAMTS13水平对EMS患者复发的预测价值。 结果 EMS患者血浆ADAMTS13水平随r-AFS分期增加而显著下降，与EHP-30评分呈负相关（P < 0.001）。低血浆ADAMTS13水平、盆腔病变位置双侧、高r-AFS分期为预后不良的独立危险因素（均P < 0.05）。血浆ADAMTS13水平的计算曲线下面积（AUC）为0.889（截断值13.315，敏感度0.931，特异度0.690）。 结论 血浆ADAMTS13水平与EMS病情严重程度呈负相关，且是EMS预后不良的独立危险因素，对EMS患者预后具有一定预测价值。
关键词： 子宫内膜异位症; 血浆血管性血友病因子裂解蛋白酶水平; r-AFS分期; 预后
徐珂 , 张明哲 , 王明阳 , 刘颂 . 子宫内膜异位症患者血浆血管性血友病因子裂解蛋白酶水平与病情严重程度和预后的相关性[J]. 实用医学杂志, 2025 , 41(2) : 238 -243 . DOI: 10.3969/j.issn.1006-5725.2025.02.013
Objective To investigate the relationship between plasma von willebrand factory-lytic protease （ADAMTS13） level and the severity of the disease and its prognostic value in patients with endometriosis （EMS）. Methods 130 patients with EMS treated in the hospital from January 2019 to December 2022 were retrospectively selected. Plasma ADAMTS13 level was detected by enzyme-linked immunosorbent assay （ELISA）， and its correlation with American Fertility Society （r-AFS） stage and endometriosis Health Status Scale （EHP-30） score was analyzed. The 1-year prognosis was recorded， and the risk factors of poor prognosis were analyzed by logistic regression. Receiver operating characteristic curve （ROC） was plotted to evaluate the predictive value of plasma ADAMTS13 levels in patients with EMS. Results The plasma ADAMTS13 level of EMS patients decreased significantly with the increase of r-AFS stage， and was negatively correlated with the score of EHP-30 （P < 0.001）. Multiple factors showed that low plasma ADAMTS13 level， bilateral location of pelvic lesions and high r-AFS stage were independent risk factors for poor prognosis （all P < 0.05）. ROC analysis showed that the area under the curve （AUC） of plasma ADAMTS13 was 0.889 （cut-off point 13.315， sensitivity 0.931， specificity 0.690）. Conclusion Plasma ADAMTS13 level is negatively correlated with the severity of EMS， and is an independent risk factor for poor prognosis of EMS patients， and has a certain predictive value for prognosis of EMS patients.
Key words： endometriosis; plasma ADAMTS13 level; r-AFS staging; prognosis
| 1 | 杨如玉，梁炎春，韦雅婧，等. 缺氧诱导HIF?1α在子宫内膜异位症巨噬细胞极化异常的作用及机制研究［J］. 实用医学杂志，2022，38（8）：964-969. |
| 2 | 吴玉良，吴春玲，吴丹. 血清sFLT1、CTRP3水平与子宫内膜异位症的相关性［J］. 实用医学杂志，2023，39（14）：1798-1803. |
| 3 | MONTANARI E， REH L M， DAUSER B， et al. Serial assessment of inflammatory parameters for prediction of septic complications following surgery for colorectal endometriosis［J］. Wien Klin Wochenschr， 2022， 134（3-4）：118-124. doi:10.1007/s00508-021-01916-w |
| 4 | KAI K， JOSHI N R， BURNS G W， et al. MicroRNA-210-3p Regulates Endometriotic Lesion Development by Targeting IGFBP3 in Baboons and Women with Endometriosis ［J］. Reprod Sci， 2023， 30（10）：2932-2944. doi:10.1007/s43032-023-01253-5 |
| 5 | ZHAO X， LI X， LIU P， et al. 17β-estradiol promotes angiogenesis through non-genomic activation of Smad1 signaling in endometriosis［J］. Vascul Pharmacol， 2022， 142：106932. doi:10.1016/j.vph.2021.106932 |
| 6 | TIAN W， LIU M， LIU Y， et al. TIM-3 regulates the proliferation by BDNF-mediated PI3K/AKT axis in the process of endometriosis［J］. Mol Med， 2023， 29（1）：170. doi:10.1186/s10020-023-00768-6 |
| 7 | LIU F， ZHOU J， ZHANG X， et al. Whole-exome sequencing and functional validation reveal a rare missense variant in MMP7 that confers ovarian endometriosis risk［J］. Hum Mol Genet， 2022， 31（15）：2595-2605. doi:10.1093/hmg/ddac062 |
| 8 | HALKIDIS K， ZHENG X L. ADAMTS13 conformations and mechanism of inhibition in immune thrombotic thrombocytopenic purpura［J］. J Thromb Haemost， 2022， 20（10）：2197-2203. doi:10.1111/jth.15822 |
| 9 | BONNEZ Q， SAKAI K， VANHOORELBEKE K. ADAMTS13 and Non-ADAMTS13 Biomarkers in Immune-Mediated Thrombotic Thrombocytopenic Purpura［J］. J Clin Med， 2023， 12（19）：6169. doi:10.3390/jcm12196169 |
| 10 | LI Y， LIU H， YE S， et al. The effects of coagulation factors on the risk of endometriosis： A Mendelian randomization study［J］.BMC Med， 2023， 21（1）：195. doi:10.1186/s12916-023-02881-z |
| 11 | 中华医学会妇产科学分会子宫内膜异位症协作组. 子宫内膜异位症的诊治指南［J］. 中华妇产科杂志，2015，50（3）：161-169. |
| 12 | SOCIETY A F. Revised classification of endometriosis［J］. Fertil Steril， 1979， 43（43）：351-352. |
| 13 | JENKINSON C， KENNEDY S， JONES K G. Evaluation of the American version of the 30-item Endometriosis Health Profile （EHP-30）［J］. Qual Life Res， 2008， 17（9）：1147-1152. doi:10.1007/s11136-008-9403-9 |
| 14 | VERCELLINI P， VIGANò P， BANDINI V， et al. Association of endometriosis and adenomyosis with pregnancy and infertility［J］. Fertil Steril， 2023， 119（5）：727-740. doi:10.1016/j.fertnstert.2023.03.018 |
| 15 | LI P S， PENG X M， NIU X X， et al. Efficacy of acupuncture for endometriosis-associated pain： A multicenter randomized single-blind placebo-controlled trial［J］. Fertil Steril， 2023， 119（5）：815-823. doi:10.1016/j.fertnstert.2023.01.034 |
| 16 | MADARATI H， SINGH K， SPARRING T， et al. Reviewing the dysregulation of adamts13 and vwf in sepsis［J］. Shock， 2024， 61（2）：189-196. doi:10.1097/shk.0000000000002291 |
| 17 | KHALIQUE S， NASH S， NATRAJAN R. Definitive study shows no association between ARID1A mutation status and clinical outcome in endometriosis-related ovarian cancers［J］.J Pathol， 2022， 258（1）：1-3. doi:10.1002/path.5973 |
| 18 | ZHU T， DU Y， JIN B. Identifying Immune Cell Infiltration and Hub Genes Related to M2 Macrophages in Endometriosis by Bioinformatics Analysis［J］. Reprod Sci， 2023， 30（11）：3388-3399. doi:10.1007/s43032-023-01227-7 |
| 19 | VIVIANO M， BENAGIANO G， GUO S W， et al. Why do oestrogens matter： Systematic review and meta-analysis assessing GnRH antagonists， considering add-back therapy， for endometriosis-associated pain［J］.Reprod Biomed Online， 2024， 49（4）：104321. doi:10.1016/j.rbmo.2024.104321 |
| 20 | 黄春芝， 刘青蓝， 苏冉， 等. 青少年子宫内膜异位症药物治疗选择及药物治疗进展［J］. 中国临床药理学与治疗学， 2024， 29（5）： 535-542. |
| 21 | ZHANG J， DONG L， ZHANG S， et al. Analysis of the clinical efficacy of leuprolide acetate in the treatment of obese patients with endometriosis and its role on the expression of MIF gene［J］. Cell Mol Biol （Noisy-le-grand）， 2022， 67（4）：282-288. doi:10.14715/cmb/2021.67.4.31 |
| 22 | POHL O， BARON K， RIGGS M， et al. A model‐based analysis to guide gonadotropin‐releasing hormone receptor antagonist use for management of endometriosis［J］. Br J Clin Pharmacol， 2022， 88（5）：2359-2371. doi:10.1111/bcp.15171 |
| 23 | GIOIA S， CARNEVALE R， TAVANO D， et al. Association between gut‐derived endotoxins and porto‐sinusoidal vascular disorder with portal hypertension［J］. Aliment Pharmacol Ther， 2023， 58（11-12）：1205-1216. doi:10.1111/apt.17727 |
| 24 | WANG Y， LI W， HA C. A large-scale causal analysis of gut microbiota and endometriosis associated infertility： A Mendelian randomization study［J］. Medicine （Baltimore）， 2024， 103（12）：e37383. doi:10.1097/md.0000000000037383 |
| 25 | PAN Y， WU T， SHI H. Distinct clinicopathological features of ovarian endometriosis after long-term exposure to mifepristone［J］.J Int Med Res， 2022， 50（11）：3000605221134471. doi:10.1177/03000605221134471 |
| 26 | HOLDSWORTH-CARSON S J， CHUNG J， MACHALEK D A， et al. Predicting disease recurrence in patients with endometriosis： An observational study［J］. BMC Med， 2024， 22（1）：320. doi:10.1186/s12916-024-03508-7 |
/
| 〈 |
|
〉 |